ClinicalTrials.gg
CompletedNCT07405177Updated Oct 29, 2026

A Study of MK-7240 in Healthy Participants (MK-7240-009)

A Phase 1 interventional study of Tulisokibart Form 1 and Tulisokibart Form 2 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Oct 29, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a body-mass index () between 18 and 32 kg/m\^2

Exclusion criteria

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Has a history of more than 1 episode of herpes zoster infection or history of disseminated herpes zoster infection
  • Has a history of or current active tuberculosis (TB) infection or history of latent TB that was not fully treated
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Arm 1: Tulisokibart Form 1

    Participants will receive tulisokibart form 1.

    Biological: Tulisokibart Form 1

  • Experimental
    Arm 2: Tulisokibart Form 2

    Participants will receive tulisokibart form 2.

    Biological: Tulisokibart Form 2

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart

    Blood samples will be collected to determine the AUC0-inf of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  2. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tulisokibart

    Blood samples will be collected to determine the AUC0-last of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  3. Maximum Plasma Concentration (Cmax) of Tulisokibart

    Blood samples will be collected to determine the Cmax of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: At designated timepoints up to 14 weeks

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: At designated timepoints up to 14 weeks

  3. Time to Maximum Plasma Concentration (Tmax) of Tulisokibart

    Blood samples will be collected to determine the Tmax of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  4. Apparent Clearance (CL/F) of Tulisokibart

    Blood samples will be collected to determine the CL/F of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  5. Apparent Volume of Distribution (V/F) of Tulisokibart

    Blood samples will be collected to determine the V/F of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  6. Apparent Terminal Half-life (t1/2) of Tulisokibart

    Blood samples will be collected to determine the t1/2 of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  7. Apparent Terminal Elimination Rate constant (Kel) of Tulisokibart

    Blood samples will be collected to determine the Kel of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  8. Ratio of AUC0-Last/AUC0-Inf of Tulisokibart

    Blood samples will be collected to determine the ratio of AUC0-last/AUC0-inf of tulisokibart.

    Time frame: At designated timepoints up to 14 weeks

  9. Area Under the Concentration-Time Curve from Time 0 to Day 14 (pAUC0-14) of Tulisokibart

    Blood samples will be collected to determine pAUC0-14 of tulisokibart.

    Time frame: At designated timepoints up to 14 days

07

Study locations

2 sites
  • Nucleus Network ( Site 0002)
    Brisbane, Queensland 4006, Australia
  • Nucleus Network ( Site 0001)
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Sep 2026, 6 months.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 12, 2026
StartActual
Mar 5, 2026
Primary completionActual
Sep 19, 2026
CompletionActual
Oct 12, 2026was Sep 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Primary completion
Sep 3, 2026→Sep 19, 2026
moved 2 times, Sep 25, 2026 – Oct 14, 2026
Study completion
Sep 3, 2026→Oct 12, 2026
moved 2 times, Sep 25, 2026 – Oct 29, 2026
Show all 3 updates
  1. Oct 29, 2026
    Study completion Sep 19, 2026→Oct 12, 2026
    + 1 other change: verification date
  2. Oct 14, 2026
    Primary completion Sep 15, 2026→Sep 19, 2026
  3. Sep 25, 2026
    Active, not recruiting→Completed
    Primary completion Sep 3, 2026→Sep 15, 2026 (now actual)
    Study completion Sep 3, 2026→Sep 19, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07405177
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Mar 5, 2026
Primary completion
Sep 19, 2026
Completion
Oct 12, 2026
Last update
Oct 29, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion